6,7-二氢-5H-环戊并[b]吡啶1-氧化物 | 90685-58-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 6,7-二氢-5H-环戊并[b]吡啶1-氧化物
• 中文别名: 4-氯-6,7-二氢-5H-环戊烷并[B]吡啶-7-基乙酸酯
• 英文名称: 6,7-dihydro-5H-cyclopenta[b]pyridine 1-oxide
• 英文别名: 1-oxido-6,7-dihydro-5H-cyclopenta[b]pyridin-1-ium
• CAS: 90685-58-8
• 化学式: C₈H₉NO
• mdl: MFCD11110318
• 分子量: 135.166
• InChiKey: BSLCBYOXMDACSD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.375
• 拓扑面积：
  25.5
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2933990090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2,3-Cyclopentenopyridine N-oxide
Synonyms: 5H,6H,7H-Cyclopenta[b]pyridin-1-ium-1-olate

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2,3-Cyclopentenopyridine N-oxide
CAS number: 90685-58-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H9NO
Molecular weight: 135.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  6,7-二氢-5H-环戊并[b]吡啶1-氧化物 反应 3.5h， 生成 1,7-萘啶
  参考文献：
  名称：

  一种制备1,6-和1,7-萘啶的新方法

  摘要：

  取代的1，6-和1，7-萘啶可以通过简单的方法从容易得到的吡喃酮中制备。与以前的方法相比，此方法更灵活，并且可以产生更高的产量。

  DOI：

  10.1039/c39840000265
• 作为产物：
  描述：

  2,3-环戊烯并吡啶 在 双氧水 作用下， 以 溶剂黄146 为溶剂， 反应 24.0h， 以95%的产率得到6,7-二氢-5H-环戊并[b]吡啶1-氧化物
  参考文献：
  名称：

  4-（二甲氨基）吡啶平面手性衍生物的合成与拆分

  摘要：

  已经开发了一种安全，更有效的合成平面手性4-（二甲基氨基）吡啶（DMAP）衍生物的方法。配合物的外消旋混合物可以通过经典拆分方法，使用市售的酒石酸进行拆分。

  DOI：

  10.1002/adsc.200700219

文献信息

• Visible-Light-Induced C2 Alkylation of Pyridine <i>N</i>-Oxides
  作者：Wen-Man Zhang、Jian-Jun Dai、Jun Xu、Hua-Jian Xu

  DOI：10.1021/acs.joc.6b02891

  日期：2017.2.17

  A photoredox catalytic method has been developed for the direct C2 alkylation of pyridine N-oxides. This reaction is compatible with a range of synthetically relevant functional groups for providing efficient synthesis of a variety of C2-alkylated pyridine N-oxides under mild conditions. Mechanistic studies are consistent with the generation of a radical intermediate along the reaction pathway.

  已经开发了用于氧化吡啶N-氧化物的直接C 2烷基化的光氧化还原催化方法。该反应与一系列合成相关的官能团相容，以在温和的条件下提供各种C 2-烷基化的吡啶N-氧化物的有效合成。机理研究与沿着反应途径产生自由基中间体是一致的。
• Visible‐Light‐Induced <i>ortho</i> ‐Selective Migration on Pyridyl Ring: Trifluoromethylative Pyridylation of Unactivated Alkenes
  作者：Jinwon Jeon、Yu‐Tao He、Sanghoon Shin、Sungwoo Hong

  DOI：10.1002/anie.201912746

  日期：2020.1.2

  alkenes. The overall process is initiated by the selective addition of a CF3 radical to the alkene to provide a nucleophilic alkyl radical intermediate, which enables an intramolecular endo addition exclusively to the ortho-position of the pyridinium salt. Both secondary and tertiary alkyl radicals are well-suited for addition to the C2-position of pyridinium salts to ultimately provide synthetically

  对于未活化的烯烃的位点选择性三氟甲基化吡啶基化，已经实现了在吡啶基环上的光催化邻位选择性迁移。整个过程是通过将CF3自由基选择性地添加到烯烃中以提供亲核烷基自由基中间体而启动的，该中间体能够将分子内的内含物专门添加到吡啶鎓盐的邻位。仲烷基和叔烷基都非常适合于添加吡啶鎓盐的C 2-位，以最终提供具有合成价值的C 2-氟烷基官能化的吡啶。此外，该方法已成功应用于以P为中心的自由基的反应。复杂生物活性分子的后期功能化进一步证明了这种转化的效用。
• [EN] SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE<br/>[FR] INHIBITEURS À PETITE MOLÉCULE DE KINASE INDUISANT NF-KB
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2020239999A1

  公开（公告）日：2020-12-03

  The present invention relates to compounds that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are envisaged to be useful for preventing or treating diseases such as cancer (such as B-cell malignancies including leukemias, lymphomas and myeloma), inflammatory disorders, autoimmune disorders, immunodermatologic disorders such as palmoplantar pustulosis and hidradenitis suppurativa, and metabolic disorders such as obesity and diabetes.

  本发明涉及抑制NIK的化合物，以及包含这些化合物的药物组合物和使用方法。这些化合物和药物组合物预期能用于预防或治疗癌症（如包括白血病、淋巴瘤和多发性骨髓瘤的B细胞恶性肿瘤）、炎症性疾病、自身免疫疾病、免疫皮肤病学疾病（如掌跖脓疱病和化脓性汗腺炎）以及代谢紊乱疾病（如肥胖和糖尿病）。
• [EN] PYRIDINEAMINE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS<br/>[FR] COMPOSÉS DE PYRIDINEAMINE UTILES EN TANT QU'INHIBITEURS DE KINASE PIM
  申请人：INCYTE CORP

  公开号：WO2016196244A1

  公开（公告）日：2016-12-08

  The present disclosure describes pyridineamine compounds, as well as their compositions and methods of use. The compounds inhibit the activity of the Pim kinases, and are useful in the treatment of diseases related to the activity of Pim kinases including, e.g., cancer, immune disorders and other diseases. Formula (I).

  本公开描述了吡啶胺化合物，以及它们的组成和使用方法。这些化合物抑制Pim激酶的活性，并且在治疗与Pim激酶活性相关的疾病方面具有用途，例如癌症、免疫紊乱和其他疾病。公式（I）。
• [EN] FACTOR XIa INHIBITORS<br/>[FR] INHIBITEURS DE FACTEUR XIA
  申请人：MERCK SHARP & DOHME

  公开号：WO2016168098A1

  公开（公告）日：2016-10-20

  The present invention provides a compound of Formula (I); and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.

  本发明提供了一种公式(I)的化合物；以及包含一个或多个所述化合物的药物组合物，以及使用所述化合物治疗或预防血栓、栓塞、高凝状态或纤维化变化的方法。这些化合物是选择性的因子XIa抑制剂或对因子XIa和血浆激肽酶的双重抑制剂。